HK1206246A1 - Use of high dose laquinimod for treating multiple sclerosis (laquinimod) - Google Patents
Use of high dose laquinimod for treating multiple sclerosis (laquinimod)Info
- Publication number
- HK1206246A1 HK1206246A1 HK15106789.5A HK15106789A HK1206246A1 HK 1206246 A1 HK1206246 A1 HK 1206246A1 HK 15106789 A HK15106789 A HK 15106789A HK 1206246 A1 HK1206246 A1 HK 1206246A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- laquinimod
- multiple sclerosis
- high dose
- treating multiple
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261641389P | 2012-05-02 | 2012-05-02 | |
PCT/US2013/039090 WO2013166166A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206246A1 true HK1206246A1 (en) | 2016-01-08 |
Family
ID=49514859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15106789.5A HK1206246A1 (en) | 2012-05-02 | 2015-07-16 | Use of high dose laquinimod for treating multiple sclerosis (laquinimod) |
Country Status (21)
Country | Link |
---|---|
US (3) | US20130303569A1 (xx) |
EP (1) | EP2844255A4 (xx) |
JP (2) | JP2015515985A (xx) |
KR (1) | KR20150013658A (xx) |
CN (2) | CN104284663A (xx) |
AR (1) | AR090885A1 (xx) |
AU (1) | AU2013256352A1 (xx) |
BR (1) | BR112014027010A2 (xx) |
CA (1) | CA2870684A1 (xx) |
CL (1) | CL2014002935A1 (xx) |
EA (1) | EA201492010A1 (xx) |
HK (1) | HK1206246A1 (xx) |
IL (1) | IL235337A0 (xx) |
MX (1) | MX2014013039A (xx) |
PE (1) | PE20150161A1 (xx) |
PH (1) | PH12014502447A1 (xx) |
SG (1) | SG11201406594UA (xx) |
TW (2) | TW201804997A (xx) |
UY (1) | UY34775A (xx) |
WO (1) | WO2013166166A1 (xx) |
ZA (1) | ZA201408820B (xx) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014008731A2 (pt) | 2011-10-12 | 2017-04-25 | Teva Pharma | tratamento de esclerose múltipla com combinação de laquinimode e fingolimode |
JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗TNEα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
KR20140138725A (ko) | 2012-02-16 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도 |
US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
BR112015007782A2 (pt) * | 2012-10-12 | 2017-07-04 | Teva Pharma | laquinimod para reduzir danos talâmicos na esclerose múltipla |
MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
AU2014216199A1 (en) * | 2013-02-15 | 2015-09-03 | Teva Pharmaceutical Industries Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
AR098924A1 (es) * | 2013-12-23 | 2016-06-22 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
EP3137092A4 (en) * | 2014-04-29 | 2017-10-11 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
UA127744C2 (uk) * | 2018-07-20 | 2023-12-20 | Мерк Патент Гмбх | Спосіб лікування та профілактики розсіяного склерозу з застосуванням сполуки заміщеного амінопіримідину (варіанти) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
ES2572811T3 (es) * | 2004-09-09 | 2016-06-02 | Yeda Research And Development Co., Ltd. | Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos |
WO2007146331A1 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
RS54328B1 (en) * | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS |
EP2523668A1 (en) * | 2010-01-13 | 2012-11-21 | Ramot at Tel-Aviv University Ltd | Treatment of multiple sclerosis |
BR112014008731A2 (pt) * | 2011-10-12 | 2017-04-25 | Teva Pharma | tratamento de esclerose múltipla com combinação de laquinimode e fingolimode |
AU2014216199A1 (en) * | 2013-02-15 | 2015-09-03 | Teva Pharmaceutical Industries Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
-
2013
- 2013-04-29 AR ARP130101459A patent/AR090885A1/es unknown
- 2013-04-29 TW TW106117959A patent/TW201804997A/zh unknown
- 2013-04-29 TW TW102115308A patent/TW201347762A/zh unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/es not_active Application Discontinuation
- 2013-05-01 EA EA201492010A patent/EA201492010A1/ru unknown
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/zh active Pending
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/ko not_active Application Discontinuation
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/es not_active Application Discontinuation
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/ja not_active Withdrawn
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/zh active Pending
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/es unknown
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en active Application Filing
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/pt not_active IP Right Cessation
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/es unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-07-16 HK HK15106789.5A patent/HK1206246A1/xx unknown
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ZA201408820B (en) | 2016-06-29 |
TW201347762A (zh) | 2013-12-01 |
EP2844255A4 (en) | 2015-10-14 |
PH12014502447A1 (en) | 2015-01-12 |
KR20150013658A (ko) | 2015-02-05 |
CA2870684A1 (en) | 2013-11-07 |
BR112014027010A2 (pt) | 2017-06-27 |
EA201492010A1 (ru) | 2015-06-30 |
US20130303569A1 (en) | 2013-11-14 |
AU2013256352A1 (en) | 2014-11-27 |
CL2014002935A1 (es) | 2015-03-06 |
WO2013166166A1 (en) | 2013-11-07 |
PE20150161A1 (es) | 2015-02-22 |
MX2014013039A (es) | 2015-02-04 |
JP2017222691A (ja) | 2017-12-21 |
CN105832733A (zh) | 2016-08-10 |
JP2015515985A (ja) | 2015-06-04 |
TW201804997A (zh) | 2018-02-16 |
US20160000775A1 (en) | 2016-01-07 |
IL235337A0 (en) | 2014-12-31 |
SG11201406594UA (en) | 2014-11-27 |
AR090885A1 (es) | 2014-12-10 |
EP2844255A1 (en) | 2015-03-11 |
UY34775A (es) | 2013-11-29 |
US20150265592A1 (en) | 2015-09-24 |
CN104284663A (zh) | 2015-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis (laquinimod) | |
HRP20180939T1 (hr) | Kombinirana terapija za liječenje multiple skleroze | |
HK1206937A1 (en) | Methods of administering pirfenidone therapy | |
PT2857019T (pt) | Método de tratamento de esclerose múltipla | |
IL234813A0 (en) | Methods for increasing the efficacy of cd37-based therapy | |
SI2812013T1 (sl) | Formulacija za zdravljenje SRČ-ja | |
PL3524260T3 (pl) | Kompozycje farmaceutyczne do leczenia braku apetytu | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
HUE044796T2 (hu) | Gyógyászati készítmény hiperkoleszterinémia kezelésére | |
EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
IL236718A (en) | Vegfr-3 inhibitors for the preparation of drugs for the treatment of liver carcinoma | |
IL244620A0 (en) | A drug combination including laquinimod for the treatment of multiple sclerosis | |
HK1210421A1 (en) | Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3- | |
HK1206633A1 (en) | Composition for treatment of warts | |
EP2800763A4 (en) | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | |
PL2812351T3 (pl) | Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego | |
IL228464A (en) | Quinolone analogues for use in the preparation of MS drugs |